Search results
Showing 1 to 4 of 4 results for vanzacaftor-tezacaftor-deutivacaftor
Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.